Latest Retinitis pigmentosa Stories
BOSTON, May 12, 2011 /PRNewswire-USNewswire/ -- Scientists from Schepens Eye Research Institute are the first to regenerate large areas of damaged retinas and improve visual function using IPS cells (induced pluripotent stem cells) derived from skin.
Disorders of the eye are excellent targets for gene therapy because the ocular environment is readily accessible, relatively easy to monitor, and sequestered from the rest of the body.
Prospects for recovery of lost vision have brightened with the release of new scientific findings showing that the use of gentle near infra-red light can reverse damage caused by exposure to bright light, up to a month after treatment.
In a major breakthrough in the field of regenerative medicine, scientists have for the first time created a part of the eye critical for vision using animal stem cells.
Retinitis pigmentosa is an inherited eye disorder characterized by progressive loss of vision that in many instances leads to legal blindness at the end stage.
A new implant designed to help the blind has allowed three test patients to see the shapes of objects just days after they were fitted with the device.
BOSTON, Oct. 21 /PRNewswire/ -- Dr. Tatsuo Hirose will receive the Schepens Eye Research Institute 2010 Distinguished Alumni Award at the Annual Meeting on Friday, October 22, 2010.
Today's Scientific Program of the 2010 American Academy of Ophthalmology (AAO) - Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting includes a report on beta carotene's ability to improve vision in people with certain incurable retinal diseases.
BOSTON, Aug. 18 /PRNewswire/ -- Dr. Eli Peli, senior scientist and vision rehabilitation researcher at Schepens Eye Research Institute, has won the 2010 Edwin H. Land Medal. The prize is given each year in honor of Edwin H.
In one of only two studies of its kind, a study from researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts demonstrates that non-viral gene therapy can delay the onset of some forms of eye disease and preserve vision.